Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $41.13

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $41.13.

A number of brokerages have issued reports on AKRO. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Tuesday, June 11th. Bank of America assumed coverage on Akero Therapeutics in a research report on Monday, April 22nd. They issued a “neutral” rating and a $30.00 price objective on the stock. Evercore ISI dropped their price objective on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research report on Wednesday, May 15th. Wolfe Research initiated coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 2,825 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $22.64, for a total transaction of $63,958.00. Following the completion of the transaction, the insider now directly owns 74,867 shares of the company’s stock, valued at approximately $1,694,988.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Catriona Yale sold 2,825 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $22.64, for a total value of $63,958.00. Following the completion of the sale, the insider now directly owns 74,867 shares of the company’s stock, valued at $1,694,988.88. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $19.29, for a total value of $96,450.00. Following the completion of the transaction, the chief operating officer now owns 253,306 shares of the company’s stock, valued at approximately $4,886,272.74. The disclosure for this sale can be found here. Insiders have sold 205,529 shares of company stock valued at $5,452,376 over the last three months. 7.94% of the stock is owned by company insiders.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently modified their holdings of the business. TD Asset Management Inc raised its position in shares of Akero Therapeutics by 23.7% during the 2nd quarter. TD Asset Management Inc now owns 154,592 shares of the company’s stock worth $3,627,000 after purchasing an additional 29,600 shares during the period. Rhumbline Advisers grew its position in shares of Akero Therapeutics by 30.3% during the second quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock worth $2,518,000 after acquiring an additional 24,940 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Akero Therapeutics by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after purchasing an additional 61,988 shares during the period. SG Americas Securities LLC boosted its stake in Akero Therapeutics by 191.2% during the 2nd quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock valued at $341,000 after purchasing an additional 9,532 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its position in shares of Akero Therapeutics by 30.0% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,521 shares of the company’s stock worth $720,000 after buying an additional 6,590 shares during the period.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock opened at $25.17 on Monday. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.87 and a beta of -0.28. The firm’s fifty day simple moving average is $23.65 and its 200-day simple moving average is $23.12. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12. Akero Therapeutics has a 12 month low of $11.25 and a 12 month high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.90) EPS for the quarter, meeting analysts’ consensus estimates of ($0.90). As a group, equities analysts forecast that Akero Therapeutics will post -3.82 earnings per share for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.